kidney transplant program (FCB-Pharmicell)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namekidney transplant program (FCB-Pharmicell)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsRejection of renal transplantation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPending (Clinical)
Highest Status in ChinaN/A
Originator CompaniesFcb-Pharmicell
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFcb-Pharmicell
Active IndicationsN/A
Inactive IndicationsRejection of renal transplantation

Other Information

ATC CodeN/A
Related LinksN/A